Dephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicity

Toxicology Letters

Volumn 166, Issue 3, 2006, Pages 189-199

  Maniratanachote, Rawiwan ^a   Minami, Keiichi ^a   Katoh, Miki ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a Graduate School of Natural Science and Technology   (Japan)

Author keywords

Cytotoxicity; Dephosphorylation; Ribosomal protein P0; Thiazolidinedione; Troglitazone; Two dimensional electrophoresis

Indexed keywords

BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE INHIBITOR; RIBOSOME PROTEIN; ROSIGLITAZONE; SILVER; TROGLITAZONE;

AMINO ACID SEQUENCE; ARTICLE; CELL PROTECTION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN ELECTROPHORESIS; PROTEIN ISOLATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; SEQUENCE ANALYSIS; SILVER STAINING; TWO DIMENSIONAL ELECTROPHORESIS;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMANS; ECHOCARDIOGRAPHY; HUMANS; HYDROGEN PEROXIDE; IMMUNOPRECIPITATION; ISOELECTRIC FOCUSING; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; OXIDANTS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 33748781166     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2006.07.303     Document Type: Article

References (39)

1. Bae M.A., and Song B.J. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol. Pharmacol. 63 (2003) 401-408
2. Ballesta J.P.G., Rodriguez-Gabriel M.A., Bou G., Briones E., Zambrano R., and Remacha M. Phosphorylation of the yeast ribosomal stalk. Functional effects and enzymes involved in the process. FEMS Microbiol. Rev. 23 (1999) 537-550
3. Barnard G.F., Staniunas R.J., Bao S., Mafune K., Steele Jr. G.D., Gollan J.L., and Chen B.L. Increase expression of human ribosomal phosphoprotein P0 messenger RNA in hepatocellular carcinoma and colon carcinoma. Cancer Res. 52 (1992) 3067-3072
4. Bova M.P., Tam D., McMahon G., and Mattson M.N. Troglitazone-induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol. Lett. 155 (2005) 41-50
5. Brockstedt E., Rickers A., Kostka S., Laubersheimer A., Döken B., Wittmann-Liebold B., Bommert K., and Otto A. Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. J. Biol. Chem. 273 (1998) 28057-28064
6. Csordas A., Wick G., and Bernhard D. Hydrogen peroxide-mediated necrosis induction in HUVECs is associated with an atypical pattern of caspase-3 cleavage. Exp. Cell Res. 312 (2006) 1753-1764
7. Freid J., Everitt D., and Boscia J. Rosiglitazone and hepatic failure. Ann. Intern. Med. 132 (2000) 164
8. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., and Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37 (1988) 1549-1558
9. Funk C., Pantze M., Jehle L., Ponelle C., Scheuermann G., Lazendic M., and Gasser R. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of the bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology 167 (2001) 83-98
10. Funk C., Ponelle C., Scheuermann G., and Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59 (2001) 627-635
11. Gardner O.S., Shiau C.W., Chen C.S., and Graves L.M. Peroxisome proliferator-activated receptorγ-independent activation of p38 MAPK by troglitazone involves calcium/calmodulolin-dependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. J. Biol. Chem. 280 (2005) 10109-10118
12. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., and Juarbe H.M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129 (1998) 36-38
13. Gonzalo P., Lavergne J.P., and Reboud J.P. Pivotal role of the P1 N-terminal domain in the assembly of the mammalian ribosomal stalk and in the proteosynthetic activity. J. Biol. Chem. 276 (2001) 19762-19769
14. Gonzalo P., and Reboud J.P. The puzzling lateral flexible stalk of the ribosome. Biol. Cell 95 (2003) 179-193
15. Hasler P., Brot N., Weissbach H., Parnassa A.P., and Elkon K.B. Ribosomal proteins P0, P1 and P2 are phosphorylated by casein kinase II at their conserved carboxyl termini. J. Biol. Chem. 266 (1991) 13815-13820
16. Holcik M., and Sonenberg N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 6 (2005) 318-327
17. Isley W.L., and Oki J.C. Rosiglitazone and liver failure. Ann. Intern. Med. 133 (2000) 393
18. Lebovitz H.E., Kreider M., and Freed M.I. Evaluation of liver function in type 2 diabetic patients during clinical trials. Diabetes Care 25 (2002) 815-821
19. Lee Y.J., and Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J. Biol. Chem. 274 (1999) 19792-19798
20. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome-activated receptor γ (PPARγ). J. Biol. Chem. 270 (1995) 12953-12956
21. Lemasters J.J., Nieminen A.L., Qian T., Trost L.C., Elmore S.P., Nishimura Y., Crowe R.A., Cascio W.E., Bradham C.A., Brenner D.A., and Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta 1366 (1998) 177-196
22. Maniratanachote R., Minami K., Katoh M., Nakajima M., and Yokoi T. Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines. Toxicol. Sci. 83 (2005) 293-302
23. Neuschwander-Tetri B.A., Isley W.L., Oki J.C., Ramrakhiani S., Quiason S.G., Phillips N.J., and Brunt E.M. Troglitazone-induced hepatic failure leading to liver transplantation. Ann. Intern. Med. 129 (1998) 38-41
24. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331 (1994) 1188-1193
25. Palakurthi S.S., Aktas H., Grubissich L.M., Mortensen R.M., and Halperin J.A. Anticancer effects of thaiazolidinediones are independent of peroxisome proliferators-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res. 61 (2001) 6213-6218
26. Palomba L., Sestili P., Columbaro M., Falcieri E., and Cantoni O. Apoptosis and necrosis following exposure of U937 cells to increasing concentrations of hydrogen peroxide: the effect of the poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide. Biochem. Pharmacol. 58 (1999) 1743-1750
27. Remacha M., Jimenez-Diaz A., Santos C., Briones E., Zambrano R., Gabriel M.A.R., Guarinos E., and Ballesta J.P.G. Proteins P1, P2, and P0, components of the eukaryotic ribosome stalk. New structural and functional aspects. Biochem. Cell Biol. 73 (1995) 959-968
28. Rich B.E., and Stietz J.A. Human acidic ribosomal phosphoproteins P0, P1 and P2: analysis of cDNA clones, in vitro synthesis, and assembly. Mol. Cell Biol. 7 (1987) 4065-4074
29. Rodriguez-Gabriel M.A., Remacha M., and Ballesta J.P.G. Phosphorylation of ribosomal protein P0 is not essential for ribosome function but can affect translation. Biochemistry 37 (1998) 16620-16626
30. Rothwell C., McGuire E.J., Altrogge D.M., Masuda H., and de la Iglesia F.A. Chronic toxicity in monkeys with the thiazolidinedione antidiabetic agent troglitazone. J. Toxicol. Sci. 27 (2002) 35-47
31. Saito T., Ikeda M., Endo T., Tsurugi K., and Onaya T. Increased expression of acidic ribosomal protein (P0) mRNA after phorbol ester treatment of cultured rat thyroid (FRTL-5) cells. Biochem. Biophys. Res. Commun. 203 (1994) 780-788
32. Shibuya A., Watanabe M., Fujita Y., Saigenji K., Kuwao S., Takahashi H., and Takeuchi H. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 21 (1998) 2140-2143
33. Tchórzewski M. The acidic ribosomal P proteins. Int. J. Biochem. Cell Biol. 34 (2002) 911-915
34. Tirmenstein M.A., Hu C.X., Gales T.L., Maleeff B.E., Narayanan P.K., Kurali E., Hart T.K., Thomas H.C., and Schwartz L.W. Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69 (2002) 131-138
35. Toyoda M., Takagi H., Horiguchi N., Kakizaki S., Sato K., Takayama K., and Mori M. A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50 (2002) 563-567
36. Watanabe T., Ohashi Y., Yasuda M., Takaoka M., Furukawa T., Yamoto T., Sanbuissho A., and Manabe S. Was it possible to predict liver dysfunction caused by troglitazone during the nonclinical safety studies?. Iyakuhin Kenkyu 30 (1999) 537-546
37. Watkins P.B., and Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338 (1998) 916-917
38. Yamamoto Y., Nakajima M., Yamazaki H., and Yokoi T. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci. 70 (2001) 471-482
39. Zampieri S., Degen W., Ghirardello A., Doria A., and van Venrooij W.J. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 60 (2001) 72-76